Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.
Jim Cramer takes a closer look at Sirius XM Radio, Shopify, Teledoc, Sarepta Therapeutics, Pilgrim's Pride.
It's not about fashion missteps, says Jim Cramer. Who cares what the products look like if there's no one in the stores?
This will be the investors' verdict on the results of Roche's APHINITY study of Perjeta in adjuvant breast cancer treatment that were released Monday morning.